247 related articles for article (PubMed ID: 23417566)
1. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
Takabayashi N; Murata K; Tanaka S; Kawakami K
Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Saini SD; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.
Chau SH; Sluiter RL; Kievit W; Wensing M; Teichert M; Hugtenburg JG
Drugs Aging; 2017 May; 34(5):375-386. PubMed ID: 28361278
[TBL] [Abstract][Full Text] [Related]
7. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
8. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
9. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care.
García Rodríguez LA; Johansson S; Nagy P; Cea Soriano L
Thromb Haemost; 2014 Jan; 111(1):131-9. PubMed ID: 24153412
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Sáez ME; González-Pérez A; Johansson S; Nagy P; Rodríguez LA
J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):378-86. PubMed ID: 25501499
[TBL] [Abstract][Full Text] [Related]
11. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Peura DA; Wilcox CM
Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
[TBL] [Abstract][Full Text] [Related]
12. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
[TBL] [Abstract][Full Text] [Related]
13. Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid.
Cea Soriano L; Bueno H; Johansson S; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):463-9. PubMed ID: 22298501
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
15. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
16. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
[TBL] [Abstract][Full Text] [Related]
17. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
[TBL] [Abstract][Full Text] [Related]
18. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
